Efficacy of HER2-targeted therapy seems to be both tumor type– and alteration type–specific (as well as variant allele–specific within the subset of ERBB2mut tumors; ref. 10), and each therapy is associated with a unique spectrum of response/resistance (10, 40). The gene discussed is ERBB2; the disease is neoplasm.